Multicenter clinical experience of real life Dalbavancin use in gram-positive infections

Area of Science:

• Infectious Diseases
• Pharmacology
• Clinical Medicine

Background:

• Dalbavancin is a lipoglycopeptide with a long half-life, approved for acute bacterial skin and soft tissue infections.
• Limited clinical data exist for its use in complex gram-positive bacterial infections like endocarditis, prosthetic joint infections (PJI), and osteomyelitis.

Purpose of the Study:

• To evaluate the real-world indications, safety, tolerability, and long-term outcomes of dalbavancin use.
• To assess the efficacy of dalbavancin in treating challenging gram-positive bacterial infections.

Main Methods:

• A multicenter, retrospective study involving 101 patients treated with dalbavancin in Austria from September 2016 to March 2018.
• Data collection focused on infection types, treatment dosages, concomitant antimicrobial use, and 90-day outcomes.
• Safety and tolerability were key assessment parameters.

Main Results:

• The primary indications were prosthetic joint infections (31%), osteomyelitis (29%), and endocarditis (25%), often in off-label settings.
• A high clinical success rate of 89% was observed.
• Dalbavancin demonstrated excellent safety and tolerability, with side effects reported in only 3% of patients.

Conclusions:

• Dalbavancin is effectively used in real-world settings for off-label treatment of PJI, osteomyelitis, and endocarditis.
• The drug exhibits a high success rate and favorable safety profile in these indications.
• Dalbavancin represents a viable alternative treatment option for complex gram-positive bacterial infections.